Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss ... Aligos Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.63 million ...

Alagille Syndrome (ALGS) is a genetic, multisystem disorder that affects several organs in the body such as the liver, heart, and skeletal system. It is a complex condition with different symptoms and ...

Keros Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry ... Aligos Therapeutics, Inc. (ALGS), another stock in the same industry, has yet to report results ...

LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently being evaluated ... a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

LIVMARLI has received orphan designation for ALGS and PFIC. LIVMARLI is currently ... a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...